Literature DB >> 22851716

P6981, an arylstibonic acid, is a novel low nanomolar inhibitor of cAMP response element-binding protein binding to DNA.

Jianfei Zhao1, Jason R Stagno, Lyuba Varticovski, Eric Nimako, Vikas Rishi, Kathy McKinnon, Rhone Akee, Robert H Shoemaker, Xinhua Ji, Charles Vinson.   

Abstract

Several basic leucine zipper (B-ZIP) transcription factors have been implicated in cancer, substance abuse, and other pathological conditions. We previously identified arylstibonic acids that bind to B-ZIP proteins and inhibit their interaction with DNA. In this study, we used electrophoretic mobility shift assay to analyze 46 arylstibonic acids for their activity to disrupt the DNA binding of three B-ZIP [CCAAT/enhancer-binding protein α, cyclic AMP-response element-binding protein (CREB), and vitellogenin gene-binding protein (VBP)] and two basic helix-loop-helix leucine zipper (B-HLH-ZIP) [USF (upstream stimulating factor) and Mitf] proteins. Twenty-five arylstibonic acids showed activity at micromolar concentrations. The most active compound, P6981 [2-(3-stibonophenyl)malonic acid], had half-maximal inhibition at ~5 nM for CREB. Circular dichroism thermal denaturation studies indicated that P6981 binds both the B-ZIP domain and the leucine zipper. The crystal structure of an arylstibonic acid, NSC13778, bound to the VBP leucine zipper identified electrostatic interactions between both the stibonic and carboxylic acid groups of NSC13778 [(E)-3-(3-stibonophenyl)acrylic acid] and arginine side chains of VBP, which is also involved in interhelical salt bridges in the leucine zipper. P6981 induced GFP-B-ZIP chimeric proteins to partially localize to the cytoplasm, demonstrating that it is active in cells. P6981 inhibited the growth of a patient-derived clear cell sarcoma cell line whose oncogenic potential is driven by a chimeric protein EWS-ATF1 (Ewing's sarcoma protein-activating transcription factor 1), which contains the DNA binding domain of ATF1, a B-ZIP protein. NSC13778 inhibited the growth of xenografted clear cell sarcoma, and no toxicity was observed. These experiments suggest that antimony containing arylstibonic acids are promising leads for suppression of DNA binding activities of B-ZIP and B-HLH-ZIP transcription factors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22851716      PMCID: PMC3477234          DOI: 10.1124/mol.112.080820

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  51 in total

Review 1.  C/EBPs: recipients of extracellular signals through proteome modulation.

Authors:  Claus Nerlov
Journal:  Curr Opin Cell Biol       Date:  2008-03-21       Impact factor: 8.382

Review 2.  Ion channels and intracellular signaling proteins as potential targets for novel therapeutics for addictive and depressive disorders.

Authors:  Antonello Bonci; William A Carlezon
Journal:  Pharmacol Ther       Date:  2005-10       Impact factor: 12.310

3.  Oncogenic MITF dysregulation in clear cell sarcoma: defining the MiT family of human cancers.

Authors:  Ian J Davis; Jessica J Kim; Fatih Ozsolak; Hans R Widlund; Orit Rozenblatt-Rosen; Scott R Granter; Jinyan Du; Jonathan A Fletcher; Christopher T Denny; Stephen L Lessnick; W Marston Linehan; Andrew L Kung; David E Fisher
Journal:  Cancer Cell       Date:  2006-06       Impact factor: 31.743

4.  Inhibition of CCAAT/enhancer binding protein family DNA binding in mouse epidermis prevents and regresses papillomas.

Authors:  Won Jun Oh; Vikas Rishi; Andras Orosz; Michael J Gerdes; Charles Vinson
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

5.  Activated cAMP response element binding protein is overexpressed in human mesotheliomas and inhibits apoptosis.

Authors:  Arti Shukla; Marcus W Bosenberg; Maximilian B MacPherson; Kelly J Butnor; Nicholas H Heintz; Harvey I Pass; Michele Carbone; Joseph R Testa; Brooke T Mossman
Journal:  Am J Pathol       Date:  2009-10-08       Impact factor: 4.307

6.  Arylstibonic acids: novel inhibitors and activators of human topoisomerase IB.

Authors:  Hyeongnam Kim; John H Cardellina; Rhone Akee; James J Champoux; James T Stivers
Journal:  Bioorg Chem       Date:  2008-05-27       Impact factor: 5.275

7.  Buffer optimization of thermal melt assays of Plasmodium proteins for detection of small-molecule ligands.

Authors:  Gregory J Crowther; Alberto J Napuli; Andrew P Thomas; Diana J Chung; Kuzma V Kovzun; David J Leibly; Lisa J Castaneda; Janhavi Bhandari; Christopher J Damman; Raymond Hui; Wim G J Hol; Frederick S Buckner; Christophe L M J Verlinde; Zhongsheng Zhang; Erkang Fan; Wesley C van Voorhis
Journal:  J Biomol Screen       Date:  2009-05-21

8.  Inhibition of CREB function in mouse epidermis reduces papilloma formation.

Authors:  Julian Rozenberg; Vikas Rishi; Andras Orosz; Jaideep Moitra; Adam Glick; Charles Vinson
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

9.  Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids.

Authors:  Lauren A Seiple; John H Cardellina; Rhone Akee; James T Stivers
Journal:  Mol Pharmacol       Date:  2007-11-27       Impact factor: 4.436

10.  MolProbity: all-atom structure validation for macromolecular crystallography.

Authors:  Vincent B Chen; W Bryan Arendall; Jeffrey J Headd; Daniel A Keedy; Robert M Immormino; Gary J Kapral; Laura W Murray; Jane S Richardson; David C Richardson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-12-21
View more
  5 in total

Review 1.  Advances in targeting nucleocapsid-nucleic acid interactions in HIV-1 therapy.

Authors:  Divita Garg; Bruce E Torbett
Journal:  Virus Res       Date:  2014-07-12       Impact factor: 3.303

Review 2.  Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases.

Authors:  Vladimir N Uversky; Vrushank Davé; Lilia M Iakoucheva; Prerna Malaney; Steven J Metallo; Ravi Ramesh Pathak; Andreas C Joerger
Journal:  Chem Rev       Date:  2014-05-15       Impact factor: 60.622

3.  Identification, synthesis and evaluation of substituted benzofurazans as inhibitors of CREB-mediated gene transcription.

Authors:  Fuchun Xie; Bingbing X Li; Candice Broussard; Xiangshu Xiao
Journal:  Bioorg Med Chem Lett       Date:  2013-07-31       Impact factor: 2.823

Review 4.  What turns CREB on? And off? And why does it matter?

Authors:  André Steven; Michael Friedrich; Paul Jank; Nadine Heimer; Jan Budczies; Carsten Denkert; Barbara Seliger
Journal:  Cell Mol Life Sci       Date:  2020-04-28       Impact factor: 9.261

5.  Systemic Inhibition of CREB is Well-tolerated in vivo.

Authors:  Bingbing X Li; Ryan Gardner; Changhui Xue; David Z Qian; Fuchun Xie; George Thomas; Steven C Kazmierczak; Beth A Habecker; Xiangshu Xiao
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.